Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terri Wrin

Showing results (21-30 of 106) with videos related to

Pageof 11
Sort By:
Plos One|August 17, 2010
Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studiesDouglas H Smith, Peggy Winters-Digiacinto, Misrach Mitiku, et al.
Journal of Virology|October 9, 2002
Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adultsJason D Barbour, Terri Wrin, Robert M Grant, et al.
Journal of Virology|May 29, 2009
Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodiesSara M O'Rourke, Becky Schweighardt, William G Scott, et al.
Journal of Virology|August 13, 2010
Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virusSara M O'Rourke, Becky Schweighardt, Pham Phung, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 5, 2011
Combined antiretroviral therapy and immune pressure lead to in vivo HIV-1 recombination with ancestral viral genomesMaria José Buzón, Terri Wrin, Francisco M Codoñer, et al.
AIDS (London, England)|January 31, 2003
Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment responseSteven G Deeks, Robert M Grant, Terri Wrin, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2004
Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutationsKirsten L White, James M Chen, Nicolas A Margot, et al.
AIDS (London, England)|May 21, 2005
HIV-1 pol replication capacity predicts disease progressionEric S Daar, Karen L Kesler, Terri Wrin, et al.
AIDS (London, England)|March 29, 2002
Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptionsJavier Martinez-Picado, Kristina Morales-Lopetegi, Terri Wrin, et al.
AIDS (London, England)|May 29, 2004
Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infectionBerta Rodés, Carlos Toro, Ellen Paxinos, et al.
Pageof 11

Showing results (21-30 of 106) with videos related to

Sort By:
Pageof 11
Plos One|August 17, 2010
Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studiesDouglas H Smith, Peggy Winters-Digiacinto, Misrach Mitiku, et al.
Journal of Virology|October 9, 2002
Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adultsJason D Barbour, Terri Wrin, Robert M Grant, et al.
Journal of Virology|May 29, 2009
Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodiesSara M O'Rourke, Becky Schweighardt, William G Scott, et al.
Journal of Virology|August 13, 2010
Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virusSara M O'Rourke, Becky Schweighardt, Pham Phung, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 5, 2011
Combined antiretroviral therapy and immune pressure lead to in vivo HIV-1 recombination with ancestral viral genomesMaria José Buzón, Terri Wrin, Francisco M Codoñer, et al.
AIDS (London, England)|January 31, 2003
Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment responseSteven G Deeks, Robert M Grant, Terri Wrin, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2004
Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutationsKirsten L White, James M Chen, Nicolas A Margot, et al.
AIDS (London, England)|May 21, 2005
HIV-1 pol replication capacity predicts disease progressionEric S Daar, Karen L Kesler, Terri Wrin, et al.
AIDS (London, England)|March 29, 2002
Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptionsJavier Martinez-Picado, Kristina Morales-Lopetegi, Terri Wrin, et al.
AIDS (London, England)|May 29, 2004
Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infectionBerta Rodés, Carlos Toro, Ellen Paxinos, et al.
Pageof 11